Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study

Y. Endo, T. Koga, S. Y. Kawashiri, S. Morimoto, A. Nishino, M. Okamoto, S. Tsuji, A. Takatani, T. Shimizu, R. Sumiyoshi, T. Igawa, N. Iwamoto, K. Ichinose, M. Tamai, H. Nakamura, T. Origuchi, Y. Ueki, T. Yoshitama, N. Eiraku, N. MatsuokaA. Okada, K. Fujikawa, H. Hamada, T. Tsuru, S. Nagano, Y. Arinobu, T. Hidaka, Y. Tada, A. Kawakami

研究成果: ジャーナルへの寄稿学術誌査読

3 被引用数 (Scopus)

抄録

Objective: To determine whether the positivity of baseline anti-Ro/Sjögren’s syndrome antigen A (SSA) antibodies influences the response to abatacept, we compared therapeutic responses between anti-Ro/SSA antibody-negative and -positive patients with rheumatoid arthritis (RA) using a multicentre RA ultrasonography prospective cohort. Method: We reviewed Japanese patients with RA who started abatacept as the first biological disease-modifying anti-rheumatic drug between June 2013 and April 2018. We assessed 28-joint Disease Activity Score–erythrocyte sedimentation rate (DAS28-ESR) change between baseline and 6 or 12 months after treatment in RA patients treated with abatacept, and European League Against Rheumatism (EULAR) response at 6 and 12 months. The Global OMERACT-EULAR Synovitis Score (GLOESS) was calculated at baseline and at 6 and 12 months. Results: Overall, 51 patients were enrolled and divided into anti-Ro/SSA antibody-negative and -positive groups of 35 and 16, respectively. Median age at baseline was significantly higher in the anti-Ro/SSA antibody-negative group (p = 0.04). The retention rate and percentage of EULAR good responders at 12 months were significantly higher in the anti-Ro/SSA antibody-negative group (both p = 0.02). Anti-Ro/SSA antibody-negative patients exhibited larger decreases in both DAS28-ESR and DAS28-C-reactive protein at 12 months than anti-Ro/SSA antibody-positive patients (p = 0.02 and 0.04, respectively). GLOESS decreased significantly at 6 months in anti-Ro/SSA antibody-negative patients (p = 0.03). Multivariate analyses showed that anti-Ro/SSA antibody positivity was an independent factor associated with change in the DAS28-ESR at 6 months (p < 0.05). Conclusion: Anti-Ro/SSA antibody positivity predicts a poor response to abatacept and low retention rate.

本文言語英語
ページ(範囲)15-19
ページ数5
ジャーナルScandinavian Journal of Rheumatology
50
1
DOI
出版ステータス出版済み - 2021

!!!All Science Journal Classification (ASJC) codes

  • リウマチ学
  • 免疫アレルギー学
  • 免疫学

フィンガープリント

「Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル